SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending as it approaches Nasdaq compliance following its recent reverse split, a key de-risking event that has ignited community discussion around its low float. Investors are eagerly anticipating imminent FDA End-of-Phase 2 feedback for its promising IHL-42X sleep apnea drug, fueling speculation of a potential short squeeze and significant upside.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending after securing Japanese marketing approval for its groundbreaking Alpha DaRT technology, which the community views as a significant global validation and de-risking event. This, alongside strong financial reports and imminent clinical trial readouts, is fueling widespread bullish sentiment and discussions of its undervaluation and substantial upside potential.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is actively discussed following its first GAAP profitable quarter, strong Q4 performance, and a new $500M stock buyback, with bulls optimistic about its Agentic AI direction and potential government contracts, while others express concern over conservative revenue guidance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East tensions and reported attacks on oil tankers near the Strait of Hormuz are driving a sharp rise in crude oil prices, as the community debates whether strategic reserve releases can effectively counter the ongoing supply risks.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to its aggressive expansion into defense technology with recent strategic acquisitions, including BIRD Aerosystems for missile protection and a merger with Mistral Inc., complemented by new multi-million dollar counter-drone system orders. The market is keenly watching whether these moves will catalyze significant revenue growth and a short squeeze, or if ongoing share dilution will continue to temper price action.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to persistent acquisition rumors from major pharmaceutical companies like Eli Lilly and AstraZeneca, fueled by reports from a reputable French publication, highlighting its promising ulcerative colitis treatment and robust clinical data. The community is actively discussing a potential bidding war given the drug's innovative profile and upcoming data presentations, positioning it as a highly attractive target in the biotech sector.

Smart Lending AI (SLAI) is a decentralized on-chain lending protocol that lets users lock approved tokens and instantly borrow up to 50% of their USD value in ETH—without selling. Prices are calculated directly on-chain via WETH pairs, and loan risk is managed through real-time volatility and liquidity analysis. Borrowers pay a flat 5% interest, while SLAI stakers (≥50,000 tokens) enjoy zero interest benefits. Designed for active DeFi traders, SLAI enables fast, gas-efficient liquidity access while preserving token exposure.

Smart Lending AI

Smart Lending AI (SLAI) is trending after receiving a preliminary going-private proposal offering a premium over its recent trading prices, sparking community debate over a potential low-ball buyout and a significant shift in voting power to its founder. This is compounded by discussions around a strategic pivot into AI and blockchain, adding to investor interest.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Escalating geopolitical tensions in the Middle East, including disruptions in the Strait of Hormuz and attacks on oil infrastructure, are propelling crude prices higher, making Chevron a key focus as the community debates its "war premium" and significant long-term expansion opportunities in Venezuela.

ProFrac Holding Corp. engages in the provision of hydraulic fracturing, proppant production, and other completion services. It operates through the following segments: Stimulation Services, Proppant Production, Manufacturing, and Other. The Stimulation Services segment owns a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services to customers. The Proppant Production segment focuses on the provision of proppant to oilfield service providers and exploration and production companies. The Manufacturing segment is involved in the sale of products such as horsepower pumps, valves, piping, swivels, large-bore manifold systems, and fluid ends. The Other segment refers to Flotek Industries and Livewire Power, LLC. The company was founded in 2016 and is headquartered in Willow Park, TX.

ProFrac Holding Corp - Ordinary Shares - Class A

PROFRAC HOLDING CORP

ProFrac Holding Corp (ACDC) is trending following its Q4 2025 earnings report, which delivered a revenue beat against analyst estimates but also a GAAP EPS decline and a softer Q1 2026 outlook due to weather disruptions. The community is actively debating if the revenue upside can offset profitability concerns and previous underperformance, especially given its position in the volatile oilfield services sector.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is a trending topic as investors grapple with its stock movement following a quarterly earnings beat, sparking community discussion on why shares declined despite strong results and how its value-driven model performs amid evolving consumer habits and operational adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up

Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to advance a Phase 3 program in metabolic dysfunction-associated...

Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference

Altimmune (NASDAQ:ALT) executives used a presentation at the Citizens Life Sciences Conference to outline recent clinical results and development plans for pemvidutide, the company's lead drug...

Altimmune (NASDAQ:ALT) CEO Jerome Benedict Durso Buys 20,000 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Benedict Durso acquired 20,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was bought at an average price...

Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory Weaver acquired 5,000 shares of the company's stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an...

Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Benedict Durso acquired 20,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was acquired at an average...

Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of Altimmune from a "hold" rating to a "sell" rating in a research report on Saturday...

Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial

B. Riley Financial decreased their target price on shares of Altimmune from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Friday...

Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The...

Altimmune Q4 Earnings Call Highlights

Altimmune (NASDAQ:ALT) executives used the company's year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated...

<ul class="summary-bullets"><li>The company said that it had cash and cash equivalents of $340 million as of the end of February, which it deems sufficient to provide an operating runaway into 2028.&nbsp;</li><li>Altimmune has already agreed with the U.S. Food and Drug Administration on an upcoming MASH trial’s design.</li><li>Meanwhile, data from the company’s mid-stage trial of pemvidutide in Alcohol Use Disorder AUD is expected in the third quarter of 2026.</li></ul>Shares of Altimmune Inc (ALT) fell 9% on Thursday after the company reported a wider-than-expected fourth quarter loss.For Q4, the biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial">reported </a>a net loss of $0.27 per share, compared to a net loss of $0.33 in the same period of 2024, but more than a Wall Street estimate of $0.24 per share.<h2 class="st-heading-2">Cash Position</h2>Altimmune said that it had cash and cash equivalents of $340 million as of the end of February, which it deems sufficient to provide an operating runaway into 2028 based on its current expectations for the timing of its late-stage trial in Metabolic Dysfunction-Associated Steatohepatitis.“Our intent is on having the cash resources necessary to execute the MASH phase 3 trial. We'll continue to be strategic and opportunistic in our approach to securing access to the forecasted capital needed to fund the phase 3, and we'll keep you updated on our progress,” CFO Greg Weaver said.Altimmune has already agreed with the U.S. Food and Drug Administration on the upcoming trial’s design. The global late-stage trial of pemvidutide in MASH is expected to evaluate multiple doses of the drug over a 52-week treatment period with biopsy-based endpoints to support potential accelerated approval.Meanwhile, data from the company’s mid-stage trial of pemvidutide in Alcohol Use Disorder AUD is expected in the third quarter of 2026. Pemvidutide is Altimmune’s lead candidate and has also been studied in the treatment of alcohol-associated liver disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.A Stocktwits user said they are buying the dip.<stembedurl>https://www.stocktwits.com/Corpkcots/message/646685890</stembedurl>Another user expressed disappointment over the earnings but voiced hopes for a buyout deal or partnership agreement for the company.<stembedurl>https://www.stocktwits.com/Damnthisappilosthistory/message/646685060</stembedurl>Yet another said that the company has a roadmap in place and is positioning itself for bigger opportunities ahead. “Short-term drops like this do not change the company’s long-term strategy,” they said.<stembedurl>https://www.stocktwits.com/Oziboz/message/646681100</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-ceo-david-ellison-says-wbd-deal-positions-it-to-compete-more-effectively-globally-report/cZdQDDQRI3k">Paramount Skydance CEO David Ellison Says WBD Deal Positions It To Compete More Effectively Globally: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Equity

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.


Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Traders keenly watch for an imminent partnership or buyout, often citing management's consistent message of being "active and open" to strategic alternatives before Phase 3 initiation.

Many users express frustration and accuse powerful entities like Goldman Sachs of actively suppressing the stock price through short selling, despite the drug's potential.

Investors are vocal about management's communication and execution, questioning decisions around financing, Phase 3 timelines, and leadership changes.

Investor conferences disappointed many with a lack of new information, leading to frustration over recycled data and missed opportunities for fresh catalysts.

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALT News

ALTAltimmune Inc